Cavalot F, Russo I, Mattiello L, Anfossi G, Massucco P, Mularoni E, Hahn A W, Trovati M
Department of Clinical and Biological Sciences, University of Turin, Italy.
Diabetologia. 1997 Jan;40(1):67-75. doi: 10.1007/s001250050644.
It has been shown that, in streptozotocin diabetic rats, protamine-retarded insulin administered in vivo stimulates intimal hyperplasia in balloon-injured carotid artery. The aim of this study was to evaluate the influence of protamine on cultured human vascular smooth muscle cells (h VSMC), by observing its effects on adhesion, chemotaxis and proliferation. hVSMC were isolated during abdominal surgery, cultured and utilized at passages 6-10. We observed that protamine stimulates: 1) cell adhesion in the concentration range 0.04-20 micrograms/ml (analysis of variance, ANOVA, p < 0.0001); 2) cell chemotaxis in the absence of fetal calf serum (FCS) in the concentration range 1-200 micrograms/ml (ANOVA, p < 0.0001) and in the presence of 1% FCS in the concentration range 5-200 micrograms/ml (ANOVA, p < 0.0001), further enhancing the chemotaxis induced by 10% FCS in the concentration range 20-200 micrograms/ml (ANOVA, p < 0.0001); 3) cell proliferation and 3H-thymidine incorporation from 1 to 5 micrograms/ml (ANOVA, p < 0.0001); 4) cell c-fos oncoprotein nuclear expression. We also observed that protamine effects on chemotaxis, proliferation and c-fos expression are inhibited by heparin that human insulin stimulates cell proliferation and 3H-thymidine incorporation (ANOVA, p < 0.0001) at concentrations equal to or greater than 480 pmol/l and that these effects of insulin persist in the presence of protamine. In conclusion, protamine influences hVSMC behaviour by interfering with biological functions involved in atherogenesis. The concentrations used in this short-term in vitro study were higher than those probably occurring in vivo in patients chronically treated by protamine-retarded insulin preparations: further studies, therefore, are needed to evaluate the safety of protamine as a retardant of insulin action in vivo.
业已表明,在链脲佐菌素诱导的糖尿病大鼠体内,给予精蛋白锌胰岛素会刺激球囊损伤颈动脉的内膜增生。本研究的目的是通过观察精蛋白对培养的人血管平滑肌细胞(hVSMC)黏附、趋化性和增殖的影响,来评估精蛋白对这些细胞的作用。hVSMC在腹部手术期间分离,培养至第6 - 10代后使用。我们观察到精蛋白能刺激:1)在浓度范围为0.04 - 20微克/毫升时促进细胞黏附(方差分析,ANOVA,p < 0.0001);2)在无胎牛血清(FCS)时,在浓度范围为1 - 200微克/毫升促进细胞趋化性(ANOVA,p < 0.0001),在有1% FCS时,在浓度范围为5 - 200微克/毫升促进细胞趋化性(ANOVA,p < 0.0001),在浓度范围为20 - 200微克/毫升时进一步增强由10% FCS诱导的趋化性(ANOVA,p < 0.0001);3)在浓度范围为1 - 5微克/毫升促进细胞增殖和3H - 胸腺嘧啶核苷掺入(ANOVA,p < 0.0001);4)促进细胞c - fos癌蛋白的核表达。我们还观察到,肝素可抑制精蛋白对趋化性、增殖和c - fos表达的作用,人胰岛素在浓度等于或大于480皮摩尔/升时刺激细胞增殖和3H - 胸腺嘧啶核苷掺入(ANOVA,p < 0.0001),且胰岛素的这些作用在有精蛋白存在时依然持续。总之,精蛋白通过干扰参与动脉粥样硬化形成的生物学功能来影响hVSMC的行为。本短期体外研究中使用的浓度高于长期接受精蛋白锌胰岛素制剂治疗的患者体内可能出现的浓度:因此,需要进一步研究来评估精蛋白作为胰岛素体内作用延缓剂的安全性。